Skip to main content

Research Repository

Advanced Search

PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke: rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment

Reinink, Hendrik; de Jonge, Jeroen C.; Bath, Philip M.; van de Beek, Diederik; Berge, Eivind; Borregaard, Saskia; Ciccone, Alfonso; Csiba, Laszlo; Demotes, Jacques; Dippel, Diederik W.; Korv, Janika; Kurkowska-Jastrzebska, Iwona; Lees, Kennedy R; Macleod, Malcolm R.; Ntaios, George; Randall, Gary; Thomalla, Gotz; van der Worp, Bart

PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke:  rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment Thumbnail


Authors

Hendrik Reinink

Jeroen C. de Jonge

PHILIP BATH philip.bath@nottingham.ac.uk
Stroke Association Professor of Stroke Medicine

Diederik van de Beek

Eivind Berge

Saskia Borregaard

Alfonso Ciccone

Laszlo Csiba

Jacques Demotes

Diederik W. Dippel

Janika Korv

Iwona Kurkowska-Jastrzebska

Kennedy R Lees

Malcolm R. Macleod

George Ntaios

Gary Randall

Gotz Thomalla

Bart van der Worp



Abstract

Background: Elderly patients are at high risk of complications after stroke, such as infections and fever. The occurrence of these complications has been associated with an increased risk of death or dependency.
Hypothesis: Prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, or any combination of these in the first four days after stroke onset will improve functional outcome at 90 days in elderly patients with acute stroke.
Design: International, 3 × 2-factorial, randomised-controlled, open-label clinical trial with blinded outcome assessment (PROBE) in 3800 patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and an NIHSS score ≥ 6. Patients will be randomly allocated to any combination of oral, rectal, or intravenous metoclopramide (10 mg thrice daily); intravenous ceftriaxone (2000 mg once daily); oral, rectal, or intravenous paracetamol (1000 mg four times daily); or usual care, started within 24 h after symptom onset and continued for four days or until complete recovery or discharge from hospital, if earlier.
Outcome: The primary outcome measure is the score on the modified Rankin Scale at 90 days (± 14 days), as analysed with multiple regression.
Summary: This trial will provide evidence for a simple, safe and generally available treatment strategy that may reduce the burden of death or disability in patients with stroke at very low costs.
Planning: First patient included in May 2016; final follow-up of the last patient by April 2020

Citation

Reinink, H., de Jonge, J. C., Bath, P. M., van de Beek, D., Berge, E., Borregaard, S., …van der Worp, B. (in press). PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke: rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment. European Stroke Journal, https://doi.org/10.1186/ISRCTN82217627

Journal Article Type Article
Acceptance Date Mar 28, 2018
Online Publication Date Apr 30, 2018
Deposit Date May 8, 2018
Publicly Available Date Nov 10, 2020
Journal European Stroke Journal
Electronic ISSN 2396-9873
Publisher SAGE Publications
Peer Reviewed Peer Reviewed
Book Title Prevention of complications to Improve outcome in elderly patients with acute stroke - A randomised clinical trial
DOI https://doi.org/10.1186/ISRCTN82217627
Keywords Stroke, complications, elderly, ceftriaxone, metoclopramide, paracetamol
Public URL https://nottingham-repository.worktribe.com/output/929967
Publisher URL http://journals.sagepub.com/doi/abs/10.1177/2396987318772687

Files






You might also like



Downloadable Citations